HighRes Biosolutions

Executive Summary

HighRes Biosolutions is a leader in intelligent laboratory automation, offering modular platforms, precision liquid handlers, and orchestration software that unify workflows and data for life science R&D. Founded in 2005 and based in Beverly, Massachusetts, the company serves the drug discovery, genomics, and synthetic biology markets. Its technology addresses critical bottlenecks in lab productivity by enabling flexible, scalable automation that integrates with existing instrumentation and lab informatics systems. HighRes differentiates through its ability to customize solutions for complex workflows, reducing manual errors and accelerating research timelines. The company has grown organically, with a strong reputation among biopharma and academic labs, and it continues to expand its product suite to meet the rising demand for high-throughput experimentation and AI-ready data generation. While HighRes operates in a competitive space alongside larger players like Tecan and Hamilton, its focus on modularity and software orchestration positions it well for the increasing shift toward smart labs and digital transformation. The company is privately held, with no disclosed funding rounds, suggesting it may be bootstrapped or self-sustaining, which could limit near-term growth but also reduce dilution risk. Overall, HighRes Biosolutions is a niche but essential enabler of next-generation life science research.

Upcoming Catalysts (preview)

• Q4 2026Launch of Next-Generation Modular Automation Platform70% success
• Q1 2027Strategic Partnership with Major Pharma for Drug Discovery Workflow50% success
• Q2 2027Entry into Synthetic Biology Market with Specialized Workflow Solution60% success